The evolving role of precision medicine in the management of advanced sarcomas – A mini review
Open Access
- 6 August 2021
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 6, 122-131
- https://doi.org/10.25259/ijmio_6_2021
Abstract
Sarcomas are a heterogenous group of cancers, traditionally with dismal outcomes. They were initially treated with histology agnostic chemotherapy-based regimens usually centered around anthracyclines. With the availability of molecular diagnostics especially next-generation sequencing, the advanced genomics of sarcomas was slowly unveiled. Precision medicine not only enables a better diagnosis in sarcomas but also allows in identifying better targets for treatment of sarcoma subtypes. GENSARC study proved that using correct molecular diagnostics, enabled in a better diagnosis and treatment of soft tissue sarcomas (STSs). Notable examples of targeted therapies with great success in sarcomas include imatinib and other tyrosine kinase inhibitors in gastrointestinal stromal tumors, neurotrophic tyrosine receptor kinase inhibitors infantile fibrosarcoma, and crizotinib in inflammatory myofibroblastic tumors. Thus, treatment of sarcomas has been gradually changing from traditional chemotherapy-based treatments to the modern targeted therapy. In this review, we hope to impress on the evolving role of precision medicine in sarcoma subtypes especially STS.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencingNature Genetics, 2013
- Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumorsCancer, 2012
- A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusionNature Genetics, 2012
- Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcomaClinical Sarcoma Research, 2012
- Molecular characterization of an EWSR1–POU5F1 fusion associated with a t(6;22) in an undifferentiated soft tissue sarcomaCancer Genetics, 2011
- Infantile fibrosarcoma: Clinical and histologic responses to cytotoxic chemotherapyPediatric Blood & Cancer, 2009
- Clear Cell Sarcoma of Soft TissueThe American Journal of Surgical Pathology, 2008
- Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcomaCancer Genetics and Cytogenetics, 2004
- Chromosomal Translocations in Ewing's SarcomaThe New England Journal of Medicine, 1983